| Document |
Document Title |
|
WO/2011/071095 |
Disclosed is a compound which is useful as a GK activator. Studies have been made on compounds which have a GK activating action and are therefore promising as active ingredients of pharmaceutical compositions for the treatment of diabet...
|
|
WO/2011/070539 |
Compounds of Formula (II) wherein R1a is H; and R1b is C1-C6alkyl, Carbocyclyl or Het; or R1a and R1b together define a saturated cyclic amine with 3-6 ring atoms; R2a and R2b are independently H, halo, C1-C4alkyl, C1-C4haloalkyl or C1-C...
|
|
WO/2011/071048 |
Provided is an agent which is a novel drug for the treatment or prevention of diabetes in that the agent possesses serine protease-inhibiting activity and thereby inhibits an increase in the blood glucose level. The agent is a compound r...
|
|
WO/2011/070541 |
Compounds of the formula (I) wherein R1a is H; and R1b is C1-C6alkyl, Carbocyclyl or Het; or R1a and R1b together define a saturated cyclic amine with 3-6 ring atoms; R2a and R2b are independently H, halo, C1-C4alkyl, C1-C4haloalkyl or C...
|
|
WO/2011/070131 |
HIV inhibitors of formula (I) wherein R1 is halo, C1-4alkoxy, trifluoromethoxy; R2 is a group of formula (A); R3 is a group of formula (B); R4 is a group of formula (C); n is 0 or 1; A is CH or N; R5 and R6 are hydrogen, C1-4alkyl, halo;...
|
|
WO/2011/067306 |
The present invention provides a compound of formula (I) a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a p...
|
|
WO/2011/066803 |
A preparation method of ethyl 2-(3-formyl-4-hydroxyphenyl)-4-methyl-5-thiazolecarboxylate as a key intermediate of febuxostat is provided. The preparation method comprises: using thioacetamide and p-cyanophenol as raw materials which are...
|
|
WO/2011/068560 |
Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.
|
|
WO/2011/065590 |
Disclosed is a method for producing 5-(aminomethyl)-2-chlorothiazole, which comprises a step of mixing a compound represented by formula (2), a mineral acid and a nitrite salt.
|
|
WO/2011/065351 |
Disclosed is a method for producing a compound represented by formula (I) (wherein R1s, R3, n and X are as defined in formula (IV) or formula (V) below with respect to the same symbols), a salt thereof or a solvate of the compound or sal...
|
|
WO/2011/066184 |
The present invention relates to novel amine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1 -phosphate receptors.
|
|
WO/2011/065420 |
Provided is a novel method for manufacturing a 6-substituted-1-methyl-1H-benzimidazole derivative. Also provided is a manufacturing intermediate from said method. The provided method, which manufactures a 6-substituted-1-methyl-1H-benzim...
|
|
WO/2011/061277 |
Amino phenyl acetamide compounds of Formula (I):and pharmaceutically acceptable salts thereof: wherein R1, R2, R3 and Ra are as defined in the description, use of such compounds in the chemotherapy of certain parasitic protozoal infectio...
|
|
WO/2011/061330 |
The invention relates to a TRPM8 modulator for achieving a cooling effect on skin or mucous membrane.
|
|
WO/2011/059731 |
The present invention is directed to novel alkynyl derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by DPP-1.
|
|
WO/2011/058154 |
Provided herein are compounds of the formula (I) as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing ...
|
|
WO/2011/058582 |
Described are bridged compounds of the formula (I), their analogs, tautomeric forms, stereoisomers, geometrical isomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites and prod...
|
|
WO/2011/057805 |
The present invention relates to novel tubulin binding molecules of formula (I) and their use for the treatment of cancer and other diseases.
|
|
WO/2011/059042 |
Disclosed is a compound represented by formula (I) (wherein the symbols are as defined in the description) or a salt thereof, which exhibits excellent long chain fatty acid elongase 6 inhibitory activity and is useful for prevention and ...
|
|
WO/2011/054525 |
The present invention concerns compounds, some of which are novel, and their pharmaceutical applications. The compounds of the invention inhibit the enzyme lactate dehydrogenase (LDH) involved both in the metabolic process of hypoxic tum...
|
|
WO/2011/055289 |
The present invention relates to novel heteroaryl compounds of formula (I), processes for their preparation, pharmaceutical compositions containing them and their use in^the treatment of diseases or disorders mediated by Diacylglycerol a...
|
|
WO/2011/051375 |
(R,S) 2-aryl-propionamide derivatives, or their single enantiomers (R) and (S) are disclosed useful in the treatment or prevention of symptoms and disorders such as pain and inflammation associated with the bradykinin B1 pathway.
|
|
WO/2011/051673 |
The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (such as asthma or COPD); and methods of treating patients which such compounds; wherein R1 to R17 and ...
|
|
WO/2011/047432 |
The present invention relates to arylcarbonyl and heteroarylcarbonyl anthranilate compounds that may be useful as anti-fibrotic agents. The present invention also relates to methods for their preparation, pharmaceutical compositions cont...
|
|
WO/2011/046954 |
The present embodiments relate to compounds with physiological effects, such as the activation of hematopoietic growth factor receptors. The present embodiments also relate to use of the compounds to treat a variety of conditions, diseas...
|
|
WO/2011/046158 |
A rhodacyanine derivative represented by the following General Formula (1), wherein, in General Formula (1), R1, R2, and R3 each independently represent an alkyl group which may be substituted; Y1 and Y2 each independently represent a hy...
|
|
WO/2011/044506 |
The invention provides sulphone compounds and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making various sulphone compounds are provided. The compounds are contemplated to have act...
|
|
WO/2011/042526 |
The invention relates to a rubber composition for the manufacture of tyres, based on a blend of at least one diene elastomer chosen from natural rubber and synthetic polyisoprene and of one or more diene elastomer(s) chosen from the grou...
|
|
WO/2011/044506 |
The invention provides sulphone compounds according to formula (Ia) and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making various sulphone compounds are provided. The compounds ar...
|
|
WO/2011/042520 |
The invention relates to a rubber composition for producing tyres, based on at least one dienic elastomer, at least one reinforcing load, and a vulcanisation system, said vulcanisation system comprising at least one thiazole compound of ...
|
|
WO/2011/044225 |
The present disclosure is generally directed to compounds which can modulate G-protein coupled receptor 88, compositions comprising such compounds, and methods for modulating G-protein coupled receptor 88.
|
|
WO/2011/039735 |
The present invention relates to the medical use of the compound of formula 1, 2, 3 or 4:
|
|
WO/2011/039735 |
The present invention relates to the medical use of the compound of formula 1, 2, 3 or 4:
|
|
WO/2011/040449 |
Disclosed are a novel compound and a pharmaceutical product, each having a remarkable uricosuric effect. Specifically disclosed are: a novel phenol derivative represented by general formula (1) that is shown in Fig. 1; a pharmaceutically...
|
|
WO/2011/037192 |
Disclosed is a substituted amide represented by formula (I), which is useful as an active ingredient of a pharmaceutical composition, especially as an active ingredient of a pharmaceutical composition for the treatment of diseases that a...
|
|
WO/2011/029596 |
The invention provides a process for preparing a (2-aminothiazol-4-yl)-triarylmethyloxy- iminoacetic acid of the formula (I) or an ester thereof of the formula (II) wherein R1, R2 and R3 independently are optionally substituted phenyl gr...
|
|
WO/2011/031409 |
Febuxostat can be prepared from the compound of the following formula (VI); Formula (VI) has been prepared in a one-pot process by combining a compound of the following formula (II); with an organic solvent, isobutyl halide and an inorga...
|
|
WO/2011/030929 |
Use of a compound represented by formula (I), a salt thereof or a solvate of the same for inhibiting type 3 17β-hydroxysteroid dehydrogenase, and so on.
|
|
WO/2011/028255 |
Desferrithiocin analogues represented by the structural formulae described here, such as formula (I), are useful in treating conditions such as metal overload (e.g., iron overload from transfusion therapy), oxidative stress, and neoplast...
|
|
WO/2011/028492 |
Bacterial infections, including Methicillin resistant Staphylococcus aureus (MRSA) infections are a major health problem that has created a pressing need for new antibiotics. Pyridazinone, rhodanine, and pyrazolethione compounds effectiv...
|
|
WO/2011/026781 |
The invention relates to compounds of the general formula (1) or the acid addition salts thereof with organic and/or inorganic acids; as well as to the use of the compounds of the general formula (1) in medicine.
|
|
WO/2011/028255 |
Desferrithiocin analogues represented by the structural formulae described here, such as formula (I), are useful in treating conditions such as metal overload (e.g., iron overload from transfusion therapy), oxidative stress, and neoplast...
|
|
WO/2011/027290 |
This invention relates to novel purified compounds of Formula (I). The invention includes all stereoisomeric forms and all tautomeric forms of the compounds of Formula (I) and pharmaceutically acceptable salts and derivatives. The presen...
|
|
WO/2011/027888 |
Disclosed are a diamide-phenyl derivative which inhibits soluble epoxy hydrolase (sEH), and a pharmaceutically acceptable salt of the diamide-phenyl derivative. Specifically disclosed are a compound represented by formula (I), and a phar...
|
|
WO/2011/023864 |
The invention relates to compounds, in particular MMP inhibitors. The compounds of the invention have formula (1). The invention can be used in particular in the pharmaceutical field. The present invention also relates to labeled compoun...
|
|
WO/2011/021214 |
An improved process for preparing (S)-2-amino-4, 5, 6, 7-tetrahydro-6-(propylamino) benzothiazole (pramipexole) and its dihydrochloride monohydrate is provided. Pramipexole dihydrochloride is the compound represented by the following str...
|
|
WO/2011/021214 |
The present invention relates to an improved process for the preparation of of (S)-2-amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole and its pharmaceutically acceptable salts. Specifically relates to the compound represented by the...
|
|
WO/2011/017054 |
Disclosed herein are new compounds of desazadesferrothiocin polyether (DADFT- PE) analogues, as well as pharmaceutical compositions comprising them and their application as metal chelation agents for the treatment of disease. Methods of ...
|
|
WO/2011/016050 |
The present invention relates to novel compounds of the general formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvat...
|
|
WO/2011/016501 |
Disclosed is a compound represented by formula (I) (wherein the symbols are as defined in the description) or a salt thereof, which has excellent activity as an estrogen-related receptor alpha modulator and is useful as a prophylactic or...
|
